Navigation Links
New Screening Protocol Identifies More Case Of Lynch Syndrome

A new way to select patients for further testing may increase detection of Lynch syndrome, a disorder that predisposes people to developing colorectal cancer at a young age, //researchers report in the Feb. 21 issue of the Journal of the National Cancer Institute.

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is caused by mutations in DNA mismatch repair genes, the genes that fix errors that occur during DNA replication.

Kristina Lagerstedt Robinson, Ph.D., of the Karolinska University Hospital in Stockholm, and her colleagues selected a group of 285 families who had been referred to the Karolinska University Hospital for genetic counseling between 1990 and 2005 because they were at high risk for HNPCC. From those families, 112 patients were screened for mutations in mismatch repair genes, often a telltale sign of HNPCC. The screening procedure detected these mutations in 69 patients and also identified at least 57 HNPCC patients, several of whom would not have been screened under current testing practices.

"Although a population-based mutation-screening strategy has the potential to also identify nonfamilial HNPCC patients, more patients will need to be screened," the authors write. "…The most important advantage with the family history-based selection process we used is that non-HNPCC families are also identified and can be offered preventive programs."

Source-Bio-Bio Technology
'"/>




Page: 1

Related medicine news :

1. Screening device for ovarian cancer
2. Screening bypasses radical breast surgery
3. Screening of Lazy Eye
4. Screening Cost-Effective for Lung Cancer
5. Screening Newborns Questioned
6. Screening For Prostate Cancer in men over 75 Questioned
7. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
8. The Effectiveness Of Screening Tests Questioned
9. Screening Test For Early Diagnosis Of Colorectal Cancer
10. The Importance Of Skin Cancer Screening
11. Ovarian Cancer Screening Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... Raton (PRWEB) , ... September 20, 2017 , ... In ... Daily Brain Booster has already been receiving positive feedback from customers trying the product ... months. , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published ... the field of addiction and homeless services, including more than a decade of ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the ... closer to God. “Psalms of Humidity” is the creation of published author, David Waldrop, ... his life are the very same things that have shaped him into the man ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: